wiki pageCreated: 2026-04-02T07:19:08By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-proteins-caspase-9
📖 Wiki Page
protein658 wordssynced 2026-04-02
Caspase-9
Introduction
Caspase 9 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Caspase-9 is encoded by the [CASP9](/proteins/casp9-protein) gene. It is a Caspase family, initiator caspases involved in caspase-9 is the initiator caspase of the intrinsic apoptotic pathway. it is activated by the apopto... [@li1997]
Caspase-9 is synthesized as an inactive proenzyme (46 kDa) with an N-terminal prodomain. Upon activation, it forms a tetramer with two catalytic subunits.
...
Caspase-9
Introduction
Caspase 9 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Caspase-9 is encoded by the [CASP9](/proteins/casp9-protein) gene. It is a Caspase family, initiator caspases involved in caspase-9 is the initiator caspase of the intrinsic apoptotic pathway. it is activated by the apopto... [@li1997]
Caspase-9 is synthesized as an inactive proenzyme (46 kDa) with an N-terminal prodomain. Upon activation, it forms a tetramer with two catalytic subunits.
Normal Function
Caspase-9 is the initiator caspase of the intrinsic apoptotic pathway. It is activated by the apoptosome (Apaf-1 + cytochrome c) and then cleaves and activates executioner caspases-3, -6, and -7. Caspase-9 activity is regulated by Bcl-2 family proteins and inhibitor of apoptosis proteins (IAPs).
Role in Disease
Alzheimer's Disease
Mitochondrial dysfunction leads to cytochrome c release and apoptosome activation, triggering caspase-9 cascade.
Parkinson's Disease
Caspase-9 is activated in dopaminergic [neurons](/entities/neurons) following mitochondrial Complex I inhibition and PINK1/Parkin pathway dysfunction.
Stroke
Ischemic injury triggers mitochondrial permeabilization and caspase-9 mediated neuronal death.
Traumatic Brain Injury
Secondary injury involves mitochondrial dysfunction and caspase-9 activation.
Therapeutic Targeting
Caspase-9 specific inhibitors (LEHD-FMK) are being studied for neuroprotection in stroke and traumatic brain injury.
Molecular Mechanisms
Apoptosome Activation
Caspase-9 is activated through the intrinsic (mitochondrial) apoptotic pathway:
Cytochrome c release: Binds to Apaf-1 in cytoplasm
Apoptosome formation: Cytochrome c + Apaf-1 + dATP/ATP form the apoptosome
Caspase-9 recruitment: Pro-caspase-9 binds to apoptosome via CARD domains
Autoactivation: Pro-caspase-9 undergoes conformational change and auto-cleavage
Executioner caspase activation: Active caspase-9 cleaves and activates caspases-3, -6, -7
Structural Features
N-terminal CARD domain: Protein-protein interactions with Apaf-1
Prodomain: ~140 amino acids
Catalytic subunits: Large (p37) and small (p12) subunits after cleavage
Active tetramer: Two catalytic dimers
Regulation
Caspase-9 is regulated by:
IAPs (Inhibitor of [Apoptosis](/entities/apoptosis) Proteins): XIAP directly inhibits caspase-9
Bcl-2 family: Anti-apoptotic proteins (Bcl-2, Bcl-xL) prevent cytochrome c release
Phosphorylation: Akt phosphorylates caspase-9 at Ser196, inhibiting activity
Alternative splicing: Caspase-9L (long isoform) has different activity
Brain Region Vulnerability
Caspase-9 activation varies across brain regions:
High susceptibility: Hippocampal CA1 neurons, cortical layer 5 pyramidal neurons
Moderate: Dopaminergic neurons in substantia nigra
Lower: Cerebellar neurons
Animal Models
Knockout Mice
Caspase-9 knockout mice: Embryonic lethal (defects in brain development)
Conditional knockout in neurons: Protected from some forms of excitotoxicity
Transgenic Models
Neuronal caspase-9 activation reporters
Fluorescent caspase-9 substrates for in vivo imaging
Therapeutic Strategies
Inhibitors
LEHD-FMK: Irreversible caspase-9 inhibitor
Z-LEHD-FMK: Cell-permeable inhibitor
Small molecule inhibitors: Under development for stroke and TBI
Modulators
IAP antagonists (Smac mimetics): Sensitize cells to apoptosis
Bcl-2 antagonists: Enhance apoptotic sensitivity
Akt activators: Inhibit caspase-9 phosphorylation
Biomarkers
Caspase-9 activation can be measured:
Activity assays: Fluorometric substrates
Cleavage products: Western blot for p37/p10 fragments
Caspase-9 activity in CSF: Potential biomarker for neurodegeneration
Background
The study of Caspase 9 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.